Trials / Withdrawn
WithdrawnNCT00362245
Amikacin Penetration Into the Cerebrospinal Fluid
Amikacin Penetration Into the Cerebrospinal Fluid: Pharmacokinetic/Pharmacodynamic Analysis in Adults With Hospital Acquired Gram-negative Meningitis Associated With Intracranial Pressure Monitoring and Draining Devices
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Rambam Health Care Campus · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The limited available data precludes establishing an antibiotic regimen in patients suffering from bacterial meningitis after head trauma, or spontaneous bleeding Understanding the disposition of Amikacin administered intrathecally will enable to propose rational treatment of these patients.
Detailed description
The limited available data precludes establishing an antibiotic regimen in patients suffering from bacterial meningitis after head trauma, or spontaneous bleeding Understanding the disposition of Amikacin administered intrathecally will enable to propose rational treatment of these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Systemic and Intra-Thecal Amikacin Therapy |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2006-08-09
- Last updated
- 2015-11-03
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00362245. Inclusion in this directory is not an endorsement.